Compare BMHL & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | GOSS |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 101.2M |
| IPO Year | N/A | 2018 |
| Metric | BMHL | GOSS |
|---|---|---|
| Price | $3.33 | $0.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 1.6K | ★ 14.1M |
| Earning Date | 08-14-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.82 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.32 |
| 52 Week High | $4.48 | $3.87 |
| Indicator | BMHL | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 24.12 |
| Support Level | $3.32 | $0.33 |
| Resistance Level | $3.89 | $0.60 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 50.00 | 14.09 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.